Key result
Among Algerian patients treated with the vitamin K antagonist acenocoumarol, the rate of bleeding complications was 22%, with overdose (OR 6.22) and drug interactions (OR 7.43) identified as significant risk factors.
Why the study?
Bleeding is the major complication of vitamin K antagonist therapy, and this study aimed to estimate hemorrhagic rates and identify risk factors in Algerian patients treated with acenocoumarol.
Cross-Sectional (n=100)
No
In Algerian patients treated with acenocoumarol, bleeding complications are frequent (22%) and are significantly driven by VKA overdose and drug-drug interactions.
Bleeding risk with acenocoumarol may warrant closer INR monitoring in Algerian patients; leaves open need for prospective validation of modifiable factors.
Background: The major complication of vitamin K antagonist (VKA) therapy is bleeding. This study aimed to estimate the rate of hemorrhagic accidents and identify the hemorrhagic factors in Algerian patients treated by the VKA, acenocoumarol.Methods: We performed a cross-sectional study in patients undergoing VKA therapy, followed in the cardiology department of the University Hospital of Sidi Bel Abbes.Results: One hundred patients were included. We recorded 22 cases of bleeding. Overdose and concomitant use of drugs that interfere with the acenocoumarol effect are significant risk factors of bleeding.Conclusions: Knowledge of predictive factors for VKA-related excessive anticoagulation seems to be of the utmost importance for improving patient management. There is a need for a national registry to assess the efficacy and safety of drug use in the short and long term. This pilot study is a cornerstone in the development of oral anticoagulation therapy monitoring in our region.
No takes yet. Share an insight, caveat, or question.
Belkacemi et al. (2021) conducted a cross-sectional in Patients undergoing vitamin K antagonist therapy (n=100). Acenocoumarol was evaluated on Bleeding complications. Among Algerian patients treated with the vitamin K antagonist acenocoumarol, the rate of bleeding complications was 22%, with overdose (OR 6.22) and drug interactions (OR 7.43) identified as significant risk factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: